Agios Pharm

Agios Pharmaceuticals is leaning heavily on its lead therapy mitapivat for near- to medium-term growth after pipeline setbacks and rising competition in sickle cell disease. Pyrukynd and Aqvesme together generated $44.7 million in worldwide net revenues in the second quarter of 2026, up 259.3% year over year, following the January 2026 U.S. launch of Aqvesme for adults with alpha- or beta-thalassemia. Aqvesme recorded 442 cumulative prescriptions from REMS-certified U.S. physicians as of June 30, 2026, up from 242 at the end of the first quarter, while the European Commission approved Pyrukynd for thalassemia in May 2026. Agios has submitted a supplemental new drug application for mitapivat in sickle cell disease under the accelerated approval pathway, and the FDA has granted priority review with a final decision expected by Nov. 1, 2026. The company discontinued its next-generation PK activator tebapivat in mid-2026 after setbacks in lower-risk myelodysplastic syndromes and sickle cell disease, and it faces competition from Novo Nordisk's etavopivat, which Novo Nordisk plans to file for approval in the fourth quarter of 2026, as well as from Bristol Myers Squibb's Reblozyl and Novartis' Adakveo.

Agios Pharmaceuticals reported worldwide net revenues of $44.7 million for mitapivat in the second quarter of 2026, up from $12.5 million a year earlier, driven by the U.S. launch of AQVESME in thalassemia and early ex-U.S. demand. The company recorded 442 cumulative AQVESME prescriptions as of June 30, 2026, and its supplemental New Drug Application for mitapivat in sickle cell disease was granted FDA Priority Review with a PDUFA goal date of November 1, 2026. Agios also licensed cevidoplenib, a next-generation oral SYK inhibitor for immune thrombocytopenia, and advanced AG-236 into Phase 2/3 development for polycythemia vera. Net loss narrowed to $100.7 million from $112.0 million in the prior-year quarter, while cash, cash equivalents, and marketable securities stood at $964.8 million as of June 30, 2026.

Zacks Equity Research has identified five biotech companies that are expected to beat earnings estimates in their upcoming second-quarter 2026 reports. The stocks are Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed, and Agios Pharmaceuticals, each combining a positive Earnings ESP with a Zacks Rank of 1, 2, or 3. Harmony Biosciences carries an Earnings ESP of +14.14% and a Zacks Rank #1, with a consensus estimate of 97 cents per share, and reports on August 4 before the open. Acadia Pharmaceuticals has an Earnings ESP of +25.00% and a Zacks Rank #2, with a consensus of 6 cents per share, reporting after the close on August 4. Biogen shows an Earnings ESP of +220.79% and a Zacks Rank #3, with a consensus of 94 cents per share, and reports on July 29 before the open. Insmed has an Earnings ESP of +22.32% and a Zacks Rank #3, with a consensus loss of 69 cents per share, reporting on August 6 before the open. Agios Pharmaceuticals has an Earnings ESP of +12.67% and a Zacks Rank #3, with a consensus loss of $1.86 per share, and reports on July 30 before the open.

Agios Pharmaceuticals announced that the FDA has accepted its supplemental new drug application for mitapivat to treat sickle cell disease under priority review, setting a PDUFA date of November 1, 2026. The application is supported by Phase 2 and Phase 3 RISE UP trials involving 176 participants, which showed improved hemoglobin levels and reduced pain crises. Mitapivat is an oral pyruvate kinase activator already approved for PK deficiency and thalassemia. A confirmatory Phase 3 REIGNITE trial is ongoing under the accelerated approval pathway. Agios shares rose 11.27% to $41.60 following the news.

Agios Pharmaceuticals shares have risen 35% over the past six months, driven by growing investor confidence in the commercial potential of its two marketed products. The biggest catalyst was the FDA approval of Aqvesme in December 2025 for the treatment of adult patients with alpha- or beta-thalassemia, making it the first FDA-approved drug for that indication. Agios reported strong early adoption of Aqvesme in first-quarter 2026, with worldwide mitapivat revenues more than doubling year over year. The company also secured European Union approval for mitapivat in thalassemia last month and submitted a regulatory filing to expand the label into sickle cell disease. Additionally, Agios in-licensed global rights to cevidoplenib, a late-stage oral spleen tyrosine kinase inhibitor for immune thrombocytopenia with estimated peak annual U.S. sales potential of up to $1 billion, while discontinuing development of tebapivat for lower-risk myelodysplastic syndromes after a mid-stage study failed to meet efficacy targets.